Wells Fargo keeps Hold on Pfizer stock. It gains 1.03 percent

Published on 10/20/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock costs EUR 26.39 on October 20, 2026 versus the Xetra close. Q2 revenue reached USD 15.03 billion versus USD 14.40 billion consensus.

Targets and results set the frame

Wells Fargo kept a Hold rating and a USD 28.00 target on October 16, 2026.
Pfizer reported USD 15.03 billion of second-quarter 2026 revenue against USD 14.40 billion consensus.
Pfizer stock trades at EUR 26.39 at 11:08 a.m. CEST at Lang & Schwarz on October 20, 2026, 1.03 percent above the Xetra close of October 19, 2026.
Pfizer is scheduled to report third-quarter 2026 results on November 3, 2026.

Moderner Architektur-Render eines unbeschrifteten Glas-Hochhauses, Symbolbild für Pfizer Inc — Architektur-Render eines modernen Glas-Hochhauses steht sinnbildlich für Pfizer Inc., ISIN US7170811035, Pharma-Konzern, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 26.39 at Lang & Schwarz on October 20, 2026, 1.03 percent above the Xetra close of October 19, 2026 at EUR 26.12. The market is weighing a recent Wells Fargo rating and Pfizer's next earnings date.

In a report released on October 16, 2026, Wells Fargo analyst Derek Archila maintained a Hold rating on Pfizer and set a USD 28.00 price target, while RBC Capital maintained Hold with a USD 25.00 target, according to The Globe and Mail. The split targets frame a cautious analyst backdrop.

Three target changes shape the setup

On October 6, 2026, Scotiabank raised its target from USD 30.00 to USD 33.00 while keeping Outperform, as reported by Yahoo Finance. On October 9, 2026, BofA raised its target from USD 27.00 to USD 29.00 and kept Neutral, according to Markets Insider. The latest Wells Fargo report therefore added a lower target without changing the Hold view.

What does the next report need to show?

Pfizer's second-quarter 2026 revenue was USD 15.03 billion against USD 14.40 billion consensus, a 4.38 percent beat. Adjusted diluted earnings per share came to USD 0.77, and management raised the midpoint of full-year 2026 revenue guidance by USD 500 million to a range of USD 60.50 billion to USD 62.50 billion, according to Yahoo Finance.

Chronology matters for the next catalyst. Pfizer raised its Scotiabank target to USD 33.00 on October 6, 2026, BofA raised its target to USD 29.00 on October 9, 2026, and Wells Fargo maintained Hold with a USD 28.00 target on October 16, 2026.

Dates investors can mark

Pfizer's third-quarter 2026 performance report and analyst call are scheduled for November 3, 2026, according to the company's Pfizer. The next ex-dividend date is November 6, 2026, according to MarketBeat.

Pfizer stock stays above the Xetra close

The Lang & Schwarz quote places Pfizer stock at EUR 26.39 on October 20, 2026 at 11:08 a.m. CEST, up 1.03 percent versus the EUR 26.12 Xetra close from October 19, 2026. The primary listing is on the NYSE, where the finance snapshot showed a USD 167.8 billion market capitalization and a USD 23.62 to USD 29.88 52-week range as of October 19, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.